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Summary
Background Many psychosocial and psychological interventions are used in patients with schizophrenia, but their 
comparative efficacy in the prevention of relapse is not known. We aimed to evaluate the efficacy, acceptability, and 
tolerability of psychosocial and psychological interventions for relapse prevention in schizophrenia.
Methods To conduct this systematic review and network meta-analysis we searched for published and unpublished 
randomised controlled trials that investigated psychosocial or psychological interventions aimed at preventing relapse 
in patients with schizophrenia. We searched EMBASE, MEDLINE, PsycINFO, BIOSIS, Cochrane Library, WHO 
International Clinical Trials Registry Platform, and ClinicalTrials.gov up to Jan 20, 2020, and searched PubMed up to 
April 14, 2020. We included open and masked studies done in adults with schizophrenia or related disorders. We 
excluded studies in which all patients were acutely ill, had a concomitant medical or psychiatric disorder, or were 
prodromal or “at risk of psychosis’’. Study selection and data extraction were done by two reviewers independently 
based on published and unpublished reports, and by contacting study authors. Data were extracted about efficacy, 
tolerability, and acceptability of the interventions; potential effect moderators; and study quality and characteristics. 
The primary outcome was relapse measured with operationalised criteria or psychiatric hospital admissions. We did 
random-effects network meta-analysis to calculate odds ratios (ORs) or standardised mean differences (SMDs) with 
95% CIs. The study protocol was registered with PROSPERO, CRD42019147884.
Findings We identified 27 765 studies through the database search and 330 through references of previous reviews 
and studies. We screened 28 000 records after duplicates were removed. 24 406 records were excluded by title and 
abstract screening and 3594 full-text articles were assessed for eligibility. 3350 articles were then excluded for a variety 
of reasons, and 244 full-text articles corresponding to 85 studies were included in the qualitative synthesis. Of these, 
72 studies with 10 364 participants (3939 females and 5716 males with sex indicated) were included in the network 
meta-analysis. The randomised controlled trials included compared 20 psychological interventions given mainly as 
add-on to antipsychotics. Ethnicity data were not available. Family interventions (OR 0·35, 95% CI 0·24–0·52), 
relapse prevention programmes (OR 0·33, 0·14–0·79), cognitive behavioural therapy (OR 0·45, 0·27–0·75), family 
psychoeducation (OR 0·56, 0·39–0·82), integrated interventions (OR 0·62, 0·44–0·87), and patient psychoeducation 
(OR 0·63, 0·42–0·94) reduced relapse more than treatment as usual at 1 year. The confidence in the estimates ranged 
from moderate to very low. We found no indication of publication bias.
Interpretation We found robust benefits in reducing the risk of relapse for family interventions, family psychoeducation, 
and cognitive behavioral therapy. These treatments should be the first psychosocial interventions to be considered in 
the long-term treatment for patients with schizophrenia.
Funding German Ministry for Education and Research.
Copyright © 2021 Elsevier Ltd. All rights reserved.
Introduction 
Schizophrenia is one of the most debilitating disorders 
worldwide.1 Relapse is associated with high costs for 
hospital admissions and unemployment and loss of 
productivity. Additionally, relationships are often jeop­
ardised and there is a risk of suicide.2 This situation has 
an impact in terms of burden for patients, families and 
society.
Antipsychotics are effective for the prevention of relapse,3 
but they are associated with considerable side­effects, and 
according to a Cochrane review, 24% of patients relapse 
within 1 year despite drug treatment.4,5 Various psychosocial 
and psychological interventions have been developed for 
people with schizophrenia. Such non­pharmaco logical 
interventions might play an important role in the 
prevention of psychotic episodes.6–9
However, several major limitations to the available 
body of evidence regarding psychosocial interventions in 
the maintenance therapy of schizophrenia have been 
identified. Firstly, previous reviews were not specifically 
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focused on the maintenance treatment of stable patients, 
but rather on the general population of patients with 
schizophrenia, mainly in the acute phase, and just 
measured relapse among many other outcomes.6–9 
Secondly, the evidence is limited to pairwise meta­ 
analyses that investigated single interventions, mainly in 
comparison with standard care, and only two Cochrane 
reviews have compared psychological interventions for 
the prevention of relapse directly with each other.10,11 With 
these two exceptions, psychological interventions for the 
prevention of relapse have not been compared with each 
other, resulting in no information on a comprehensive 
ranking of all psychosocial interventions evaluated in 
randomised controlled trials for the prevention of 
relapse in patients with schizophrenia. Finally, the 
length of time that these interventions should be 
provided for remains unclear, because in previous 
reviews, the results at different time points were not 
always consistent.6–9
A better understanding of the comparative efficacy of 
these active interventions would be important for clinical 
practice and for meaningful allocation of resources. In 
this context, we did a network meta­analysis to calculate 
relative treatment effects of psychosocial interventions 
for relapse prevention in patients with schizophrenia in 
terms of the following: (1) relapse, considering 
three different time­points, up to 26 weeks, up to 
52 weeks, and beyond; (2) other efficacy outcomes; and 
(3) acceptability (number of dropouts) and tolerability 
(adverse events).
Methods 
Search strategy and selection criteria 
In our systematic review and network meta­analysis, we 
included open and masked randomised controlled trials 
done in adults with a diagnosis of schizophrenia or 
related disorders, irrespective of the diagnostic criteria, 
without restrictions of setting, gender, or ethnicity. 
Studies including participants with other diagnoses were 
included if at least 80% of the participants had a diagnosis 
of schizophrenia, schizophreniform, or schizoaffective 
disorder. We excluded studies in which the inclusion 
criteria was acute illness, a concomitant medical or 
psychiatric disorder, or prodromal or “at risk of 
psychosis”, to ensure homogeneity in the population. 
Studies in which the psychosocial intervention started at 
the end of a period of time in hospital were included, 
because such a procedure is common practice.
We included studies that compared psychosocial and 
psychological interventions that had a main target of 
relapse prevention. The interventions could be compared 
with each other or with control conditions used in 
the trials, usually treatment as usual. In this control 
condition, participants receive the standard care, which 
usually includes maintenance treatment with anti­
psychotics, but no additional specific psychosocial 
intervention. We included studies irrespective of 
publication year and language.
Since our aim was to include studies in which the 
psychosocial intervention is intended to prevent relapse, 
studies were included if relapse or rehospitalisation were 
Research in context
Evidence before this study
Schizophrenia is a common, severe, and usually chronic 
disorder. Psychosocial and psychological interventions can be 
used in combination with antipsychotics for preventing 
recurrence of psychotic episodes (relapse) in patients with 
schizophrenia. However, many different interventions have 
been developed, and whether they differ in terms of efficacy for 
relapse prevention, and to what extent, remains unclear. 
We searched PubMed (last search April 27, 2021), without 
language restrictions, with the search term (((schizophrenia)) 
AND (psychotherapy OR “psychological intervention” OR 
“psychological treatment” OR “psychosocial intervention” OR 
“psychosocial treatment”)) AND ((maintenance OR relapse)) 
and filter “Article type: Meta-analysis”, and with the search term 
((((schizophrenia)) AND (psychotherapy OR “psychological 
intervention” OR “psychological treatment” OR “psychosocial 
intervention” OR “psychosocial treatment”)) AND 
((maintenance OR relapse)) ) AND (network meta-analysis) and 
inspected 65 references. We found no network meta-analyses, 
and some outdated pairwise meta-analyses investigating single 
interventions compared with treatment as usual, except for 
two Cochrane reviews that compared cognitive behavioural 
therapy and brief psychoeducation with other psychosocial 
interventions as a group. Excluding these Cochrane reviews, 
we found no evidence on the comparative effectiveness of 
psychological and psychosocial interventions for the prevention 
of relapse in schizophrenia. Moreover, these meta-analyses did 
not specifically focus on relapse prevention, but rather 
investigated each intervention on multiple outcomes in the 
general population of patients with schizophrenia, including 
patients who were acutely ill.
Added value of this study
This study provides an overall picture of all the available 
evidence on comparative efficacy, acceptability, and tolerability 
of psychosocial and psychological interventions for relapse 
prevention in people with schizophrenia. We found a clear 
benefit in reducing the risk of relapse for family interventions, 
family psychoeducation, and cognitive behavioural therapy.
Implications of all the available evidence
We suggest that policy makers and clinicians consider giving 
priority to family interventions, family psychoeducation, 
and cognitive behavioural therapy when allocating resources 
and planning maintenance treatment for patients with chronic 
schizophrenia.
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measured among the primary outcomes according to the 
protocols or methods of the trial. For studies in which 
this information was not explicitly reported, two reviewers 
(IB and AR) independently judged whether relapse could 
be considered a primary or co­primary outcome of the 
treatment by assessing the title, outcomes structure, 
study aims, and power calculations. A detailed list 
of criteria used is reported in the appendix (p 18). We 
included studies in which the assessment of relapse was 
done at a minimum of 12 weeks after randomisation.
To identify eligible studies, we searched EMBASE, 
MEDLINE, PsycINFO, PubMed, BIOSIS, Cochrane 
Central Register of Controlled Trials, ClinicalTrials.gov 
and WHO International Clinical Trials Registry Platform 
for randomised controlled trials published up to 
Jan 20, 2020, and in PubMed up to April 14, 2020, 
that compared psychosocial interventions for relapse 
prevention with each other or with a control condition in 
people with schizophrenia. The search terms included 
terms related to schizophrenia and schizophrenia­like 
disorders, randomisation, and a great variety of terms 
related to psychosocial interventions (appendix pp 8–17). 
IB and either AR or HG­M independently screened the 
identified references and selected the finally included 
studies. IB and AR extracted data from the selected 
studies, considering all available reports. Relevant 
information was entered into a Microsoft­Access database 
especially created for this study that automatically 
detected whether independent extractions agreed.
HW and DW managed the selection and data extraction 
of studies written in Chinese. Disagreements were 
resolved by discussion among reviewers or with a third 
reviewer (SL). Additionally, IB contacted authors of 
included studies published in the past 30 years with a 
request for missing or additional data (appendix pp 19–24).
Data analysis 
The primary outcome was relapse. In case of multiple 
measures reported, we gave priority to relapse defined 
with operationalised criteria, psychiatric hospital admis­
sions, and clinical judgement, in this order. We extracted 
data for relapse at three different timepoints separately 
(up to 6 months, up to 12 months–primary time point, 
more than 12 months).
We examined overall, positive, negative, and depressive 
symptoms of schizophrenia; quality of life; adherence; 
overall functioning; and study discontinuations due 
to inefficacy as secondary efficacy outcomes. Study 
discontinuations for any reason were examined as a 
measure of acceptability. Adverse events that might have 
been connected to the intervention (reported according 
to a published classification)12 and mortality (for any 
reason, due to natural causes or suicide) were examined 
as tolerability outcomes. Data for secondary outcomes 
were extracted at study endpoint (end of the treatment).
The psychological interventions were classified 
according to the description provided in each study 
publication, with a definition of nodes described in the 
table).
In case we retrieved more reports of the same study, 
data was extracted from the one reporting about the 
highest number of patients.
We performed random­effects pairwise meta­analyses 
and a network meta­analysis in a frequentist framework 
using the package netmeta in R (version 1.2­1).13 We 
calculated odds ratios (ORs) for binary outcomes and 
standardised mean differences (SMDs) for continuous 
outcomes, both presented with 95% CIs. We also 
calculated the relative ranking for each intervention 
within the frequentist framework (as P­scores) and used 
them to present the results according to this order.14 To 
facilitate interpretation of results, we calculated absolute 
event rates for the primary outcome relapse at the 
primary time­point 12 months (appendix p 3).
Before running the network meta­analysis, we assessed 
the transitivity assumption. This assumption implies 
that studies comparing different sets of interventions are 
sufficiently similar to provide valid indirect inferences, 
which we tried to ensure by applying narrow inclusion 
criteria. We also compared the distribution of key effect 
modifiers across studies grouped by interventions 
(baseline severity, inpatient status, masking of outcome 
assessor, percentage of female patients, publication year, 
sample size, mean age, study duration).
We assumed a common heterogeneity parameter 
across the various treatment comparisons and presented 
the between­study variance τ² for each outcome. We 
characterised the amount of heterogeneity as low, 
moderate, or high using the first and third quantiles of 
their empirical distributions.15,16 
To explore potential sources of heterogeneity or 
inconsistency, we did a priori planned subgroup analyses 
for the primary outcome on the following potential effect 
modifiers:17 first­episode patients, setting (individual vs 
non­individual), inpatient status, number of sessions, 
and baseline severity.
Statistical inconsistency was evaluated separating 
indirect from direct evidence, and then testing the 
agreement of these two pieces of evidence (SIDE­test);18 
the magnitude of inconsistency factors (ratio of ORs) and 
their respective p values were used to identify the 
presence of inconsistency. We also applied the design­by­
treatment interaction model that evaluates inconsistency 
in the network.19
Sensitivity analyses were done excluding studies that 
did not employ a masked outcome assessor, studies that 
presented only completer analyses, studies with high 
overall bias, studies with researchers’ allegiance, or 
studies in which relapse or hospital admission were not 
defined explicitly as primary outcome (but only based on 
our judgement; appendix p 18). We also analysed hospital 
admissions and relapse separately. We did a sensitivity 
analysis considering patients who dropped out from the 
study as having relapsed (unless data about these patients 
See Online for appendix
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Number of studies Description of the intervention
Acceptance and 
commitment therapy
1 A manualised third-generation behavioural therapy that incorporates acceptance and mindfulness-based strategies to help patients in 
overcoming negative thoughts and feelings.
Assertive community 
treatment
3 An intensive, highly integrated approach for community mental health service delivery. The teams visit the patients at home, provide clinical 
assessments and crisis interventions, along with psychosocial and functional assistance. This can be considered as a more active form of case 
management, because it is more holistic and integrated with coordinated services that promote increased wellness for the patient.
Case management 3 Each patient is usually assigned to a case manager who contacts the patient regularly (eg, once a week) and can provide more intensive support 
in case of particularly acute needs.
Cognitive behavioural 
therapy
9 Cognitive behavioural therapy for psychosis is usually based on an individualised case formulation and the establishment of collaborative goals 
with the patient. Therapy components include the improvement of existing coping strategies, the development and practice of new ones, 
the modification of delusional beliefs and beliefs about hallucinations, and the challenge of dysfunctional schemas. Adaptive views of self are 
strengthened, including the re-evaluation of negative beliefs about the self.
Cognitive training 1 A programme of regular activities aimed to maintain or improve cognitive abilities. In the specified study, the patients received training of 
memory and attention, training of language expression and logic, coordination, and cognitive rehabilitation.
Family interventions 19 An intervention involving the relatives of the patient, which can have several different aims. These include construction of an alliance with 
relatives who care for the person with schizophrenia, reduction of adverse family atmosphere, enhancement of the capacity of relatives to 
anticipate and solve problems, maintenance of reasonable expectations for patient performance, and attainment of desirable change in 
relatives’ behaviour and belief systems.
Family psychoeducation 15 Similar to psychoeducation for patients, the following areas are usually covered: symptoms of schizophrenia, pharmacological and psychosocial 
treatments, and prevention of relapse, with a special focus on the role of the family. The intervention might be delivered to the relatives alone, 
involve the patient, or be delivered in a multi-family context. More active aspects such as coping skills might be involved, but the primary focus 
is the provision of information.
Family support 2 Mainly used as a control condition for family interventions; the aim is to control for the non-specific aspect of the treatment (for example, 
spending time with families that experience the same situation, without the provision of a systematic intervention (also defined as the social 
network placebo).
Health education 2 Lectures on general health topics (such as healthy food or physical exercise); might include relaxation training and stress reduction techniques.
Integrated interventions 11 Interventions that were explicitly defined as a combination of different treatments, for example individual cognitive behavioural therapy plus 
family intervention plus assertive outreach.
Mindfulness 1 The intervention consists of guided meditation followed by reflective group discussion aimed at facilitating understanding or metacognitive 
insight. During meditation, participants bring full awareness to difficult voices, feelings, thoughts, and images, and also become aware of 
habitual coping reactions, safety behaviours, and their effects. In meditation they practise letting go of these reactions and learn to allow and 
observe psychotic experiences without reacting. Meditation and discussion lead to insight that struggling, judging, and ruminating on 
psychotic experience creates distress, while mindful observation and acceptance of psychotic experience is empowering and calming.
Motivational 
interviewing
2 A client-centered, directive method, through which patients are engaged in strategically directed conversations about their problems. 
It explores personal ideas and ambivalences, eliciting and selectively reinforcing so-called change talk, by which discrepancies between the 
present behaviour and the patient’s own future goals are amplified. The overall goal is to increase the patient’s intrinsic motivation for change. 
In patients with schizophrenia it can be used to focus on specific impacts of illness behaviours on the patients, and provide them with 




9 Psychoeducation can be defined as the education of a person with a psychiatric disorder in subject areas that serve the goals of treatment and 
rehabilitation. In patients with schizophrenia it usually covers the following topics: symptoms of psychosis, models of psychosis, effects and 
side-effects of medication, maintenance medication, psychotherapy for psychosis, early symptoms of relapse, and relapse prevention.
Rehabilitation 6 Usually includes a prevocational day programme, recreational and social activities, apartment living, and transitional employment 
opportunities with the aim of increasing the ability of the patient to function independently in the community.
Relapse prevention 
programmes
2 Interventions that generally include education for recognising early symptoms of relapse, a system of symptoms monitoring, and a crisis plan 
and intervention in case the symptoms increase over a certain threshold.
Relatives groups 5 Support groups for relatives of patients, where they meet without the patients with the aim of sharing experiences and providing mutual 
support and emphatic discussion about caregiving experiences. The groups are usually peer led, without the direct involvement of an expert. 
The peer leader facilitates empathic and supportive responses to individual needs and concerns.
Social skills training 5 An intervention for acquiring skills necessary to live in the community. It includes teaching skills such as symptom management and relapse 
prevention, involving role-plays, problem solving, in vivo exercises, and home assignments. The therapists are instructed to model appropriate 
interaction styles and behaviours, and to teach clients how to effectively use the skills by using repetition and encouragement.
Supportive therapy 3 A group active intervention, aimed at the provision of a safe and supportive atmosphere in which to raise issues of emotional importance to 
the patients, with an emphasis on the non-specific factors of warmth and empathy. Patients can describe the narrative of their lives, including 
the effect of the illness, so that they can be helped to make sense of the timing of the illness and its nature and content with reference to strong 
and unbearable effects regarding past aspects of personal history.
Telemedicine 4 Patients and family members are regularly contacted via SMS or telephone call with the main aim of monitoring symptoms. If the symptoms 
appear to be above a certain threshold, an alert is activated and a visit with the clinician is organised.
Treatment as usual 61 Patients continue to receive standard psychiatric care. This can vary according to national and local service protocols and guidelines, but usually 
includes regular psychiatric consultations, maintenance antipsychotic medication, out-patient and community follow-up, and access to 
community-based rehabilitative activities such as day centres and drop-in centres.
Table: Description of included interventions 
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were already considered by study authors in the outcome 
provided in the study; for these studies we did not do this 
additional analysis to avoid double counting). In the main 
analysis, patients who dropped out from the study were 
not considered as having relapsed, unless explicitly stated.
Risk of bias was assessed by IB and AR using the 
Cochrane Risk of Bias tool 2 for the primary outcome 
relapse.20 The tool evaluates the domains randomisation 
process, deviations from intended interventions, missing 
outcome data, measurement of the outcome, and 
selection of the reported result. We assessed the presence 
of small­trial effects (potentially associated with 
publication bias) for the primary outcome with a 
comparison­adjusted funnel plot ordering the treatments 
from the newest to the oldest. Following this, we tested 
for asymmetry in the adjusted logORs using the Harbord­
test.21,22
We evaluated the confidence in the relative treatment 
effect estimated in the network meta­analysis for the 
primary outcome using the Confidence in Network 
Meta­Analysis framework,23 implemented in the web 
application CINeMA.24
We followed the PRISMA statement extension for 
network meta­analyses (appendix pp 5–7).25 The methods 
of the systematic review and network meta­analysis are 
described in detail in the protocol registered in 
PROSPERO, CRD42019147884; in the appendix (p 3); and 
in a specific method paper.17
Role of the funding source 
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report.
Results 
27 765 studies were identified through the database search 
and 330 identified through references of previous reviews 
and studies. 28 000 records were screened after duplicates 
were removed. After 24 406 records were excluded during 
title and abstract screening, 3594 full­text articles were 
assessed for eligibility. Following exclusion of a further 
3350 articles for a variety of reasons including different 
study design, inappropriate population, and incorrect 
intervention, 244 full­text articles corresponding to 
85 studies were included in the qualitative synthesis. Of 
these, 72 studies (involving 10 364 participants and done 
between 1971 and 2019) had usable data and were included 
in the network meta­analysis; figure 1; appendix pp 25–35).
We were able to include unpublished data for 
nine studies, owing to collaboration with the authors 
(appendix pp 19–24). The included studies provided 
comparisons of 20 psychosocial and psychological 
interventions (table).
The mean sample size per study was 142 participants 
(range 19–1268), and the median trial duration was 
52 weeks (range 2–468). Of 9655 participants with sex 
indicated, 3939 (40·8%) were female and 5716 (59·2%) 
were male. We tried to collect ethnicity data, but they were 
rarely reported. The mean duration of illness was 7·6 years 
(SD 4·2), and the mean age of participants was 32·3 years 
(SD 6). Most patients had mild symptoms of schizophrenia, 
with a mean reported Positive and Negative Syndrome 
Scale baseline score of 52·34.26
The risk of bias assessments for the included studies 
are presented in the appendix (pp 36–39). One study had 
a low overall risk of bias, 51 studies had a moderate 
overall risk, and 33 studies had a high overall risk. No 
study was rated at high risk in the randomisation process 
domain.
We found no clear evidence of violations of the transitivity 
assumption when comparing characteristics of studies 
across interventions (appendix pp 40–48). However, in 
most parameters the number of studies per comparison 
For more on CINeMA see 
http://cinema.ispm.ch
Figure 1: Study selection
*No sufficient information about inclusion criteria, or publication in another language that was not possible to 
translate.
3594 full-text articles assessed for eligibility
3350 full-text articles excluded
 450 wrong study design 
 642 wrong population
 72 wrong intervention
 1112 with relapse or hospital admission not mentioned 
  as outcome
 691 with a primary outcome that was not relapse or 
  hospital admission
 145 with relapse or hospital admission mentioned among 
  other outcomes, but with no cues that it 
  was a primary outcome
 75 declared that the main objective of the study was not 
  relapse or hospital admission
 95 duplicates
 65 awaiting assessment* 
 3 ongoing studies
244 full-text articles corresponding to 85 studies 
  included in qualitative synthesis
72 studies included in quantitative synthesis 
     (meta-analysis)
28 000 records screened
24 406 records excluded during title and abstract screening 
95 duplicates excluded
27 765 records identified through 
 database search
330 additional records identified 
 through other sources
28 095 records identified and screened for duplication
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was small, so there might have been a certain level of 
intransitivity that we were not able to detect.
In the following results discussing the effects of 
treatments, we focus on network meta­analysis results 
for which the 95% CI excluded the possibility of no 
difference between interventions. More details in terms 
of network plots, forest plots, and league tables are 
presented in the appendix (pp 49–96). 63 studies with 
19 interventions (n=9010 participants; figure 2) con­
tributed to the network meta­analysis of the primary 
outcome relapse at the primary timepoint of 12 months. 
ORs compared with treatment as usual (with 95% CIs 
excluding no effect) and corresponding percentages of 
participants who relapsed were 0·35 (95% CI 
0·24–0·52) with 16% for family interventions, 0·33 
(0·14–0·79) with 15% for relapse prevention pro­
grammes, 0·45 (0·27–0·75) with 20% for cognitive 
behavioral  therapy, 0·56 (0·39–0·82) with 23% for 
family psychoeducation, 0·62 (0·44–0·87) with 25% for 
integrated interventions, and 0·63 (0·42–0·94) with 
25% for patient psychoeducation. By contrast, 35% of 
participants receiving treatment as usual relapsed 
(figure 3 and figure 4). Family interventions were also 
associated with a lower probability to relapse than were 
integrated interventions, patient psychoeducation, 
rehab ilitation, relatives groups, case management, and 
family support (figure 4). Heterogeneity in estimates 
between studies of the same comparison was low to 
moderate; incon sistency in direct and indirect estimates 
was moderate (appendix pp 97–103).
The confidence intervals for relapse at the secondary 
timepoints of 6 months and more than 12 months usually 
overlapped with those of the primary timepoint, meaning 
similar effects. An exception was for family interventions 
and family psychoeducation, which were effective at 
12 months and longer, but not at 6 months. By contrast, 
assertive community treatment was effective only at 
6 months, but with a broad confidence interval. Cognitive 
behavioural therapy showed virtually no difference 
compared with treatment as usual at 6 months and more 
than 12 months (figure 3).
In the sensitivity and subgroup analyses, the results of 
the primary outcome were similar to the main analysis, 
with the exception of assertive community treatment, 
integrated intervention, patient psychoeducation, and 
rehabilitation, for which point estimates and confidence 
intervals showed more variation. For integrated inter­
vention, patient psychoeducation, and rehabilitation, the 
main analysis showed a superiority in comparison with 
treatment as usual, but in six or more additional analyses 
the confidence intervals included the possibility of no 
difference (figure 5; appendix pp 104–56).
Concerning secondary efficacy outcomes (appendix 
pp 60–96), almost all interventions were superior to 
control conditions with 95% CIs excluding no effect 
except for motivational interviewing, telemedicine, 
cognitive training, and case management for overall 
symptoms (31 studies on 15 treatments); integrated 
interventions, family interventions, and case manage­
ment for positive symptoms (20 studies on 
12 treatments); and assertive community treatment, 
family psychoeducation, family intervention, case 
management, and telemedicine for negative symptoms 
(21 studies on 12 treatments). The probability to drop 
out due to inefficacy was lower for cognitive behavioural 
therapy than for treatment as usual (12 studies, 
eight treatments).
Family interventions were more efficacious than were 
most other treatments in improving functioning; 
mindfulness and cognitive behavioural therapy outper­
formed treatment as usual (24 studies, 14 treatments).
Regarding the acceptability of the interventions, no 
differences emerged in overall dropout rates, except for a 
superiority of integrated interventions compared with 
treatment as usual (59 studies, 19 treatments contributing 
to the analyses).
Concerning tolerability, integrated interventions were 
associated with less non­compliance (assessed for this 
outcome as an adverse event) than was treatment as 
usual; while relapse prevention programs had a higher 
probability of non­compliance than did most of the other 
treatments (22 studies on 13 interventions). Data on other 
adverse events associated with psychological interventions 
were scarce and could not be analysed. Death was a very 
rare event and did not differ between treatments 
(22 studies with 12 treatments). Insufficient data were 
available for depressive symptoms, adherence, quality of 
life, and suicides.
Heterogeneity and inconsistency assessments for 
secondary outcomes are presented in the appendix 
Figure 2: Network plot of the primary outcome of relapse at 12 months
The lines link treatments with direct comparisons in trials. The thickness of lines corresponds to the number of 
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Figure 3: Forest plots of 
psychological interventions 
versus treatment as usual for 
the primary outcome of 
relapse at 6 months, 
12 months, and more 
than 12 months
Treatments are ranked by 
probability of being the best in 
preventing relapse (net rank) 
at the main timepoint 
(12 months). Reference 
treatment is treatment as 
usual. ORs less than 1 are in 
favour of the psychological 
intervention. Event rates were 
calculated from ORs as 
explained in the appendix 
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(pp 97–103). For many secondary outcomes the networks 
were thin and the power was low, and therefore there 
might be an inconsistency that we were not able to detect. 
We found no indication of small­study effects (comparison­
adjusted funnel plot of the primary outcome in the 
appendix, p 157; Harbord test p=0·56).
Judgements about confidence in the estimates 
(CINeMA) ranged from moderate to very low, meaning 
that further research is very likely to affect our confidence 
in the estimate of effect and is likely to change the 
estimate (figure 4; appendix pp 158–174).
Discussion 
To our knowledge, we did the first network meta­analysis 
investigating psychosocial and psychological inter ventions 
for relapse prevention. We analysed 20 interventions 
reported in 72 randomised controlled trials with 
10 364 participants.
We found that family interventions, family psycho­
education, cognitive behavioral therapy, patient psycho­
education, integrated interventions, and relapse prevention 
programmes were superior to standard care alone in 
preventing relapses at 12 months.
Overall, the interventions showed consistent patterns at 
the three time points considered, because confidence 
intervals overlapped broadly, with a few notable exceptions. 
Family interventions and family psycho education were 
not more efficacious than treatment as usual at 6 months, 
but only after 1 year. This result is consistent with the 
Cochrane review by Pharoah and colleagues.7 Assertive 
community treatment was efficacious only at 6 months 
Figure 5: Forest plots of sensitivity and subgroup analyses
Reference treatment is treatment as usual. ORs less than 1 are in favour of the 
psychological intervention. OR=odds ratios. Main=main analysis. 
SENS1=exclusion of studies in which the outcome assessor was not masked. 
SENS2=exclusion of studies that presented only completer analysis. 
SENS3=exclusion of studies with high risk of bias in the overall domain. 
SENS4=exclusion of studies with researchers’ allegiance. SENS5a=patients who 
dropped out from the study were considered as having relapsed. 
SENS6a=relapse defined with operationalised criteria. SENS6b=relapse defined 
as hospital admissions. SENS7a=exclusion of studies in which relapse or hospital 
admission was not defined explicitly as the primary outcome but on the basis of 
our judgement (only explicit). SENS7b=studies in which relapse or hospital 
admission was not defined explicitly as the primary outcome but on the basis of 
our judgement analysed alone (excluding explicit). SUB1a=studies done in 
patients with first-episode schizophrenia. SUB1b=studies done in patients with 
chronic schizophrenia. SUB3a=intervention done in individual setting. 
SUB3b=intervention done in non-individual setting (group, family). 
SUB4a=status inpatient (at enrolment in the study). SUB4b=status outpatient 
(at enrolment in the study). SUB5a_1=low number of sessions. SUB5b=high 
number of sessions. SUB6a=high baseline severity. SUB6b=low baseline severity.
Figure 4: League table of the primary outcome of relapse at 12 months
Treatments are ranked by probability of being the best in preventing relapse (net rank). Results from the network meta-analysis (mixed [network] and indirect comparisons) are presented in the lower 
left triangle and results from pairwise meta-analyses (direct comparisons) are presented in the upper right triangle. Significant results are presented in bold. Relative treatment effects are measured by 
odds ratios along with their 95% CIs. The colours of the cells in the lower triangle represent the confidence in the estimate results obtained with CINeMA: blue indicates moderate confidence, yellow 
indicates low confidence, and red indicates very low confidence. ACT=assertive community treatment. ACTP=acceptance and commitment therapy. CBT=cognitive behavioural therapy. CM=case 
management. CT=cognitive training. FI=family intervention. FP=family psychoeducation. FS=family support. HE=health education. II=integrated intervention. MI=motivational interviewing. 
PE=patient psychoeducation. RE=rehabilitation. RG=relatives groups. RPP=relapse prevention programme. ST=supportive therapy. SST=social skills training. TAU=treatment as usual. TI=telemedicine.
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and cognitive behavioural therapy was efficacious only at 
1 year, but not in the longer term. Notably, results at 
different timepoints were often from different studies, 
and fewer studies reported data at 6 months and more 
than 1 year compared with at 1 year, leading to lower power 
at these secondary timepoints.
Social skills training Supportive therapy Treatment as usual Telemedicine Intervention
Motivational interviewing Psychoeducation Rehabilitation Relapse prevention programme Relatives groups
Family intervention Family psychoeducation Family support Health education Integrated intervention
Acceptance and commitment 
therapy
Assertive community treatment Case management Cognitive behavioural therapy Cognitive training
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Family interventions were also efficacious in improving 
other outcomes such as symptoms of schizophrenia and 
functioning. Therefore, the prevention effect on relapse 
could be mediated by other factors such as reduction in 
symptoms, better functioning, direct involvement of 
family members, and better compliance. Family members 
might become more able to manage crises, reducing 
hospital admissions. A simpler intervention in the form 
of family psychoeducation was also effective in preventing 
relapses and improving symptoms. Thus, in the absence 
of resources, simple family psychoeducation might be 
offered as a minimum solution. Both family interventions 
and family psychoeducation need some time to take 
effect, reducing the risk of relapse only after 1 year. By 
contrast, the mere provision of support for relatives or 
family had no effect. The effects of different kinds of 
family interventions on relapse are under investigation in 
an ongoing network meta­analysis.27
Patient psychoeducation was more effective than was 
treatment as usual at 12 months, but not at 6 months or 
more than 12 months, but with broadly overlapping 
confidence intervals. In the Cochrane review by Xia and 
colleagues,6 patient psychoeducation was efficacious in 
preventing relapse after 1 year. This pairwise meta­
analysis had broader inclusion criteria (which is not 
possible with a network meta­analysisNMA in order not 
to break the transitivity assumption) and therefore more 
data. Furthermore, we found patient psychoeducation to 
be effective in reducing symptoms and improving 
adherence when compared with treatment as usual.
Cognitive behavioural therapy was efficacious in 
reducing relapse at 12 months and in improving many 
secondary outcomes (overall, positive, and negative 
symptoms; adherence; and functioning). The benefit in 
reduction of relapse in the longer term is unclear, 
consistent with the results of Jones and colleagues.8 
Cognitive behavioural therapy is not specifically designed 
for relapse prevention; its primary goal is to reduce 
persistent psychotic symptoms, for which it is effective.28 
Other modules of cognitive behavioural therapy could be 
developed to improve its effect for relapse prevention in 
the longer term.
Integrated interventions combine different com­
ponents as a treatment. Results were robust across 
timepoints for relapse and showed efficacy in primary 
and secondary outcomes. However, the implications for 
clinical practice are unclear, because it cannot be deduced 
whether integrated interventions are effective because 
they include more components or because certain 
components are deemed particularly effective. A 
component network meta­analysis design could help to 
ascertain the role of the specific elements of the 
integrated interventions.
Specific relapse prevention programmes focus on 
relapse prevention by monitoring early symptoms of 
relapse. Results were promising, but little evidence was 
available (two studies with 92 participants).
Psychosocial interventions such as assertive com­
munity treatment, case management, and rehabilitation 
aim at providing structure to the life of the patient 
outside of the hospital, by visiting the patient at home, 
providing a reference figure for service organisation, 
or offering rehabilitation activities. Rehabilitation had 
promising results in preventing relapse; assertive 
community treatment reduced the risk of relapse at 
6 months, while for case management the confidence 
intervals include the possibility of no difference with 
treatment as usual (only three studies). These results are 
consistent with previous broader reviews that found 
assertive community treatment effective in preventing 
relapse,29 and no protective effect for case management.30
Other psychosocial interventions did not reduce the 
risk of relapse. For some of them, this might not be 
surprising, because they are either designed with a 
different focus than relapse prevention (eg, social skills 
training), or little evidence was available (eg, cognitive 
training or telemedicine).
Overall, results on efficacy­related secondary outcomes 
showed the same patterns as the primary outcome, 
relapse.
Whether psychotherapy can cause side effects is an 
important question,12,31 but still rarely investigated. On 
the basis of our data, we could not draw conclusions on 
the tolerability of the investigated interventions. Potential 
side effects can be more easily monitored in observational 
studies that focus more on the process of psychotherapy, 
rather than the outcome, as is the case with randomised 
controlled trials. Trials have many methodological 
challenges, and investigation of weakly defined outcomes 
might be very difficult.
Our findings have the following limitations. Firstly, the 
available data for many comparisons are based on few 
studies (in some cases just one or two studies), leading to 
thinly connected networks and low statistical power to 
detect possible differences. Therefore, the results should 
be interpreted with caution, and for this reason 
hierarchies based on p values and direct comparisons 
between interventions were used only for presentation 
purposes, but not interpreted.
Secondly, risk of bias in the included studies was 
classified as some concerns or high, leading to mainly 
low confidence in the estimates evaluated with CINeMA. 
Masking of therapist and patients is not possible in 
studies on psychological interventions, introducing an 
unavoidable source of bias.
Thirdly, although we applied stringent inclusion 
criteria and identified no clear transitivity problems, 
there was heterogeneity and inconsistency for some 
outcomes. We explored potential effect modifiers, but 
found no evident role for any of the moderators 
investigated. By contrast, results were generally robust 
across additional analyses. We planned to investigate the 
role of different definitions of relapse, but because 
relapse was often poorly defined this analysis was not 
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possible, except for the separate analysis of readmission 
to hospital.
Fourth, in all the included randomised controlled trials, 
psychological interventions were offered in addition 
to pharmacological treatment. Details on medication 
received and doses are very rarely provided, so that the 
roles of the treatments are difficult to disentangle. If 
randomisation ensures that characteristics of patients 
and potential confounders, such as pharmacological 
treatment received, are equally distributed between the 
study arms, randomisation cannot address any potential 
modifying effect of pharmacological treatment received 
on the effect of the added psychological and psychosocial 
intervention. Findings about the included psychological 
and psycho social interventions must be interpreted as 
the effects of the interventions provided in addition to 
pharmacotherapy.
To overcome these limitations, high quality randomised 
controlled trials need to be done, reporting on patient 
drug therapy in detail and providing an operationalised 
definition of relapse. These trials, together with studies 
of other designs, should also investigate the mechanisms 
and specific processes of change underlying the relapse 
preventive effects of the interventions, which is important 
for their scalability and sustainability in routine care.
Finally, although patient psychoeducation, integrated 
interventions, and relapse prevention programmes were 
effective for the primary outcome, there was considerable 
variability in different subgroup and sensitivity analyses. 
By contrast, results for family interventions, family 
psychoeducation and cognitive behavioural therapy were 
robust, and their nodes were well connected in the 
networks. For this reason, although our results 
demonstrate that many psychological interventions can 
play a role in the prevention of relapse in patients with 
schizophrenia, policy makers and clinicians should 
consider giving priority to family interventions, family 
psychoeducation, and cognitive behavioural therapy 
when allocating resources and planning maintenance 
treatment for patients with schizophrenia.
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